Welcome to our dedicated page for Afya SEC filings (Ticker: AFYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Afya Limited (AFYA) is a foreign private issuer that reports to the U.S. Securities and Exchange Commission primarily through Form 20‑F and Form 6‑K. This SEC filings page centralizes access to those documents, which provide detailed information on the company’s operations as a medical education group and medical practice solutions provider in Brazil.
Afya’s Form 20‑F annual report contains audited financial statements and extensive narrative disclosures on its three reportable segments: Undergraduate, Continuing Education and Medical Practice Solutions. Investors can review segment definitions, revenue composition, key operational metrics and risk factors related to its physician‑centric ecosystem and Brazilian regulatory environment.
Throughout the year, Afya files multiple Form 6‑K reports. These include unaudited interim condensed consolidated financial statements, press releases announcing quarterly and half‑year financial results, and disclosures on specific corporate events. Examples documented in recent 6‑Ks include new share repurchase programs for Class A common shares, issuance of commercial notes by Afya Participações S.A., repayment of debentures, repurchase and cancellation of Series A perpetual convertible preferred shares, changes to the board of directors, results of the annual general meeting and the engagement of a new independent registered public accounting firm.
For investors analyzing AFYA, these filings are key sources for understanding revenue trends, adjusted EBITDA, net income, capital structure decisions and governance developments. They also provide context on Afya’s medical school seat authorizations and other regulatory milestones in Brazil’s higher education sector.
On Stock Titan, Afya’s SEC filings are updated in line with EDGAR submissions and can be paired with AI‑powered summaries that explain the main points of lengthy documents. Users can quickly identify which filings relate to financial results, capital markets transactions, governance changes or other material events, and then drill down into the full text when deeper analysis is required.
Afya Ltd Chief Executive Officer Gibbon Virgilio Deloy Capobianco reported open-market sales of Class A common shares. On April 2, he sold 20,900 shares at $14.94 per share, and on April 6, he sold 770 shares at $14.91 per share.
After these sales, he holds 108,448 Class A shares directly and an additional 200,000 Class A shares indirectly through GIBBOAT OVERSEAS LTD, which is solely owned and controlled by him. The 21,670 shares sold represent a small portion of his overall position.
Afya Ltd Chief Executive Officer Gibbon Virgilio Deloy Capobianco reported open-market sales of 21,820 Class A Common Shares of Afya Ltd over two days. He sold 19,500 shares on April 1, 2026 at $14.98 per share and 2,320 shares on March 31, 2026 at $14.92 per share.
Following these transactions, he holds 130,118 Class A Common Shares directly. He also has an indirect holding of 200,000 Class A Common Shares through GIBBOAT OVERSEAS LTD, which the footnote states is solely owned and controlled by him.
Afya Limited files its annual report prepared under IFRS, presenting consolidated results in Brazilian reais with convenience translations at R$5.5024 per US$1.00. The company operates a large medical and health‑education ecosystem in Brazil through undergraduate, continuing education and digital medical solutions.
The report emphasizes extensive risk factors: intense competition in medical and graduate education, rapid technological change including artificial intelligence, and heavy exposure to Brazilian regulation of medical school openings and enrollment caps. Afya is also highly dependent on government programs such as FIES and PROUNI, Brazilian tax reform (IBS, CBS, Pillar Two and a new 10% dividend withholding), and close MEC supervision via ENADE and ENAMED scores, which can trigger sanctions affecting seats, programs and access to public funding.
Afya Ltd Chief Executive Officer Gibbon Virgilio Deloy Capobianco reported open-market sales of Class A Common Shares. He sold 1,510 shares at $14.91 per share on March 30, 2026 and 300 shares at $15.00 per share on March 27, 2026, totaling 1,810 shares sold.
After these transactions, he directly holds 151,938 Class A Common Shares. In addition, 200,000 Class A Common Shares are held indirectly through GIBBOAT OVERSEAS LTD, which is solely owned and controlled by him, indicating a substantially larger remaining overall position.
XP Investments US, LLC submitted a Form 144 disclosing an intended sale of Class A common shares of Afya Limited.
The filing lists securities acquired under compensation plans: 36,000 shares acquired pursuant to an S-8 stock option plan on 04/25/2025 and 7,032 shares from a Restricted Share Units program on 05/01/2025.
Afya Ltd Chief Executive Officer Gibbon Virgilio Deloy Capobianco reported open-market sales of Class A common shares. On March 25, 2026, he sold 3,900 shares at $15.18 per share, and on March 26, 2026 he sold 800 shares at $15.21 per share, totaling 4,700 shares sold. After these transactions, he directly holds 153,748 Class A shares and indirectly holds 200,000 Class A shares through GIBBOAT OVERSEAS LTD, which is solely owned and controlled by him.
AFYA submitted a Form 144 notice proposing the sale of Class A common shares. The filing lists planned sale activity tied to equity compensation events, with representative entries including 23,500 and 14,051 shares acquired under company plans on 06/10/2025 and 05/01/2025.
The excerpt ties the shares to stock option and restricted share unit programs and reports transaction dates; timing and aggregate offer amount are not stated in the provided excerpt.
Afya Ltd director Esteves Nicolau Carvalho has amended his insider holdings disclosure. The Form 3/A restates his positions without reporting any new purchases or sales. He now reports indirect ownership, through NRE Capital Ventures Ltd., of 4,500,000 Class B common shares, each linked to 4,500,000 underlying Class A common shares, plus 5,321,379 Class A common shares, and direct ownership of 13,916 Class A common shares.
The amendment clarifies that NRE Capital Ventures Ltd. is owned by Carvalho and his wife, Rosangela Esteves, correcting an earlier filing that had described him as the sole owner and controller.
Afya Ltd vice president Junior Lelio de Souza has filed an initial statement of equity holdings. The filing lists stock options over 8,000 Class A common shares per grant at an exercise price of 52.0000 or 62.5900, with expiration dates from 2026 through 2033. Footnotes state these options fully vest and become exercisable three years before each expiration date, subject to continued service.
The filing also shows restricted stock units over 20,000 and 29,400 Class A common shares, which are scheduled to vest in tranches between May 1, 2026 and May 1, 2029, again conditioned on continued service. In addition, he directly holds 43,032 Class A common shares.
Afya Ltd Vice President Basolli Gomiero Mirella filed an initial ownership report showing a mix of common shares, stock options and restricted stock units tied to Class A Common Shares.
The filing lists four stock option grants, each labeled as a right to buy 26,000 Class A Common Shares at an exercise price of 59.4700 (denominated in Brazilian Reais), with expirations on May 1, 2028, May 1, 2029, May 1, 2030 and May 1, 2031. According to the footnotes, these options fully vest and become exercisable three years before their respective expiration dates, subject to continued service.
The report also shows 29,820 Class A Common Shares subject to outstanding RSUs, which are scheduled to vest as to 12,780 shares on May 1, 2026 and 17,040 shares on May 1, 2027, again contingent on continued service. In addition, the Vice President directly holds 35,265 Class A Common Shares as of the reporting date.